PeakShares LLC Invests $1.04 Million in Intuitive Surgical, Inc. $ISRG

PeakShares LLC bought a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,836 shares of the medical equipment provider’s stock, valued at approximately $1,040,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ISRG. State Street Corp raised its stake in Intuitive Surgical by 1.0% during the fourth quarter. State Street Corp now owns 15,701,591 shares of the medical equipment provider’s stock valued at $8,892,753,000 after purchasing an additional 162,264 shares in the last quarter. Capital World Investors grew its stake in shares of Intuitive Surgical by 1.7% in the 4th quarter. Capital World Investors now owns 7,856,018 shares of the medical equipment provider’s stock worth $4,449,491,000 after buying an additional 127,526 shares in the last quarter. Norges Bank purchased a new position in shares of Intuitive Surgical in the 4th quarter worth $2,856,987,000. Invesco Ltd. increased its holdings in shares of Intuitive Surgical by 17.4% in the 4th quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock worth $2,338,350,000 after buying an additional 611,268 shares during the last quarter. Finally, Fisher Asset Management LLC increased its holdings in shares of Intuitive Surgical by 1.1% in the 3rd quarter. Fisher Asset Management LLC now owns 3,889,439 shares of the medical equipment provider’s stock worth $1,739,475,000 after buying an additional 40,702 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Gary Loeb sold 400 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total transaction of $169,656.00. Following the completion of the sale, the executive vice president directly owned 5,720 shares of the company’s stock, valued at approximately $2,426,080.80. This trade represents a 6.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $420.55, for a total value of $2,365,593.75. Following the transaction, the senior vice president owned 6,463 shares of the company’s stock, valued at approximately $2,718,014.65. The trade was a 46.53% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,169 shares of company stock worth $3,059,135 over the last 90 days. Company insiders own 0.60% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on ISRG. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Intuitive Surgical from $440.00 to $366.00 and set a “sell” rating for the company in a report on Tuesday, June 2nd. UBS Group reduced their price objective on Intuitive Surgical from $570.00 to $550.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 17th. The Goldman Sachs Group set a $558.00 price objective on Intuitive Surgical in a research report on Wednesday, May 27th. Truist Financial lowered their price objective on Intuitive Surgical from $650.00 to $580.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. Finally, Leerink Partners dropped their target price on Intuitive Surgical from $622.00 to $573.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. Nineteen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $573.42.

Intuitive Surgical Stock Performance

ISRG stock opened at $406.78 on Friday. Intuitive Surgical, Inc. has a 12 month low of $396.68 and a 12 month high of $603.88. The company has a 50-day moving average price of $438.43 and a 200 day moving average price of $490.46. The stock has a market cap of $144.07 billion, a PE ratio of 49.31, a P/E/G ratio of 3.31 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, beating the consensus estimate of $2.08 by $0.42. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.62 billion. During the same period in the prior year, the firm posted $1.81 EPS. The firm’s revenue was up 23.0% compared to the same quarter last year. Sell-side analysts forecast that Intuitive Surgical, Inc. will post 8.57 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.